Factors affecting the willingness of African-American and American Indian/Alaska Native communities to engage in genetic and biomarker research: The UBIGR study

Q2 Medicine
Diane Carol Gooding , Fabu P. Carter , Emre Umucu , Carol Ann Van Hulle , Jordan P. Lewis , Megan Zuelsdorff , Shenikqua Bouges , Taryn T. James , Hector Salazar , Lytonia Floyd , James Bester , Carey E. Gleason
{"title":"Factors affecting the willingness of African-American and American Indian/Alaska Native communities to engage in genetic and biomarker research: The UBIGR study","authors":"Diane Carol Gooding ,&nbsp;Fabu P. Carter ,&nbsp;Emre Umucu ,&nbsp;Carol Ann Van Hulle ,&nbsp;Jordan P. Lewis ,&nbsp;Megan Zuelsdorff ,&nbsp;Shenikqua Bouges ,&nbsp;Taryn T. James ,&nbsp;Hector Salazar ,&nbsp;Lytonia Floyd ,&nbsp;James Bester ,&nbsp;Carey E. Gleason","doi":"10.1016/j.bionps.2024.100090","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Despite the disproportionate impact of Alzheimer’s disease (AD) dementia on Black/African-American and American Indian/Alaska Native groups, they have been underrepresented in biomarker research. Research investigating underrepresented groups’ willingness to engage in research has primarily relied on qualitative research and/or specialized samples (e.g., patients’ first-degree relatives). Similarly, extant quantitative studies include disproportionately small numbers of these participants. This investigation aimed to understand preclinical biomarker and genetic AD research participation in underrepresented groups to facilitate greater diversity in future biomarker research and clinical trials.</p></div><div><h3>Method</h3><p>We administered an online questionnaire to 599 Black/African-American, 120 American Indian/Alaska Native, and 725 NonHispanic White adults and assessed demographic characteristics and participants’ views on dementia, research, and genetic and preclinical biomarker testing. Attitudes toward research were examined using the standardized 7-item Research Attitudes Questionnaire (RAQ) measure. Using structural equation modeling, we tested <em>a priori</em> hypotheses regarding willingness to engage in AD preclinical biomarker testing. The specific survey item used as the outcome measure asked for agreement with the statement: “I would be willing to undergo any type of testing necessary if it was the only way to find out if I was at risk for AD before there were any symptoms,” answered on a Likert scale (1=strongly disagree – 7=strongly agree).</p></div><div><h3>Results</h3><p>The three groups differed significantly in their attitudes toward research, as measured by total RAQ scores. Despite no differences in opinion regarding the overall usefulness of biomarkers, the ethnoracial groups differed in their willingness to engage in preclinical biomarker testing for dementia. Path analysis revealed an excellent model fit, indicating that attitudes toward research, as measured by the RAQ, influenced biomarker testing willingness. These findings suggest the need for outreach and engagement programs to occur before attempting research recruitment, particularly with BIPOC populations.</p></div>","PeriodicalId":52767,"journal":{"name":"Biomarkers in Neuropsychiatry","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266614462400008X/pdfft?md5=219152dcb621c9bf925858357407134e&pid=1-s2.0-S266614462400008X-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in Neuropsychiatry","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S266614462400008X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Despite the disproportionate impact of Alzheimer’s disease (AD) dementia on Black/African-American and American Indian/Alaska Native groups, they have been underrepresented in biomarker research. Research investigating underrepresented groups’ willingness to engage in research has primarily relied on qualitative research and/or specialized samples (e.g., patients’ first-degree relatives). Similarly, extant quantitative studies include disproportionately small numbers of these participants. This investigation aimed to understand preclinical biomarker and genetic AD research participation in underrepresented groups to facilitate greater diversity in future biomarker research and clinical trials.

Method

We administered an online questionnaire to 599 Black/African-American, 120 American Indian/Alaska Native, and 725 NonHispanic White adults and assessed demographic characteristics and participants’ views on dementia, research, and genetic and preclinical biomarker testing. Attitudes toward research were examined using the standardized 7-item Research Attitudes Questionnaire (RAQ) measure. Using structural equation modeling, we tested a priori hypotheses regarding willingness to engage in AD preclinical biomarker testing. The specific survey item used as the outcome measure asked for agreement with the statement: “I would be willing to undergo any type of testing necessary if it was the only way to find out if I was at risk for AD before there were any symptoms,” answered on a Likert scale (1=strongly disagree – 7=strongly agree).

Results

The three groups differed significantly in their attitudes toward research, as measured by total RAQ scores. Despite no differences in opinion regarding the overall usefulness of biomarkers, the ethnoracial groups differed in their willingness to engage in preclinical biomarker testing for dementia. Path analysis revealed an excellent model fit, indicating that attitudes toward research, as measured by the RAQ, influenced biomarker testing willingness. These findings suggest the need for outreach and engagement programs to occur before attempting research recruitment, particularly with BIPOC populations.

影响非裔美国人和美洲印第安人/阿拉斯加原住民社区参与基因和生物标记研究意愿的因素:UBIGR 研究
背景尽管阿尔茨海默病(AD)痴呆症对黑人/非洲裔美国人和美国印第安人/阿拉斯加原住民群体的影响格外严重,但他们在生物标志物研究中的代表性却一直不足。调查代表性不足群体参与研究意愿的研究主要依赖于定性研究和/或专门样本(如患者的一级亲属)。同样,现有的定量研究中这些参与者的人数也少得不成比例。本调查旨在了解临床前生物标记物和遗传性AD研究在代表性不足群体中的参与情况,以促进未来生物标记物研究和临床试验的多样性。方法我们对599名黑人/非洲裔美国人、120名美国印第安人/阿拉斯加原住民和725名非西班牙裔白人成年人进行了在线问卷调查,评估了人口统计学特征以及参与者对痴呆症、研究、遗传和临床前生物标记物测试的看法。我们使用标准化的 7 项研究态度问卷 (RAQ) 对研究态度进行了调查。通过结构方程模型,我们检验了有关参与AD临床前生物标记物检测意愿的先验假设。作为结果测量的具体调查项目要求同意以下陈述:"结果根据 RAQ 总分,三组人对研究的态度存在显著差异。尽管对生物标记物的整体效用的看法没有差异,但人种组在参与痴呆症临床前生物标记物测试的意愿上存在差异。路径分析显示,模型拟合度非常高,表明由 RAQ 测定的研究态度影响了生物标记物检测的意愿。这些研究结果表明,在尝试进行研究招募之前,有必要开展外联和参与计划,尤其是针对BIPOC人群。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Biomarkers in Neuropsychiatry
Biomarkers in Neuropsychiatry Medicine-Psychiatry and Mental Health
CiteScore
4.00
自引率
0.00%
发文量
12
审稿时长
7 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信